1. A pharmaceutical tablet for oral administration containing ulipristal acetate in an amount of 3-18 wt.% Together with the following excipients: diluent in an amount of 60-95 wt.%, A binder in an amount of 0-10 wt.%, Croscarmellose sodium in an amount of 1 -10 wt.% And magnesium stearate in an amount of 0-5 wt.%. 2. The tablet according to claim 1, where the binder is in an amount of 1-10 wt.%. 3. The tablet according to claim 1, where the diluent is in an amount of 65-92 wt.%. 4. The tablet according to claim 1, where the binder is in an amount of 1.5-8.5 wt.%. 5. The tablet according to claim 1, where croscarmellose sodium is in an amount of 1.5-8.5 wt.%. 6. The tablet according to claim 1, where the magnesium stearate is in an amount of 0.5-4 wt.%. 7. The tablet according to claim 1, containing 10 wt.% Ulipristal acetate. The tablet according to claim 1, containing 5-30 mg of ulipristal acetate. A tablet according to any one of claims 1 to 8, wherein the diluent is selected from the group consisting of a monosaccharide, a disaccharide, a polyol derived from a monosaccharide and their hydrates. 10. The tablet according to claim 9, wherein the diluent is selected from the group consisting of lactose monohydrate and mannitol. A tablet according to any one of claims 1 to 8, wherein the binder is selected from the group consisting of polymers. The tablet of claim 11, wherein the binder is selected from the group consisting of hydroxypropyl methylcellulose and povidone. A tablet according to any one of claims 1 to 8, wherein the diluent is lactose monohydrate and the binder is povidone. A tablet according to any one of claims 1 to 8, containing ulipristal acetate 6-12 wt.%, Lactose monohydrate 71-87 wt.%, Povidone 4.5-5.5 wt.%, Croscarmellose sodium 4.5-5.5 wt.% and magnesium stearate 1-4 wt.%. 15. The tablet of claim 14, containing ulipristal acetate 10 wt.%, Lactose monohydrate 79 wt.%, Povidone 5 ma1. Фармацевтическая таблетка для перорального введения, содержащая
